简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
01093.HK
CSPC Pharmaceutical Group (01093.HK): Albumin-bound Paclitaxel for Injection (II) Approved for Marketing
Tags：
CSPC Pharmaceutical Group
01093.HK
2026-06-15
CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
Tags：
CSPC PHARMA
01093.HK
Clinical Trial
2026-06-10
CSPC PHARMA(01093.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 859.79 million, YoY decrease of 41.83%
Tags：
CSPC PHARMA
01093.HK
2026-05-27
CSPC PHARMA(01093.HK): Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials for Advanced Solid Tumors
Tags：
CSPC PHARMA
01093.HK
ClinicalTrialApproval
2026-04-15
Previous
1
2
Featured News
Research
HK shares Newly Listed Stocks Tracking Weekly Report: B&K CORP-B Leads with 68% Weekly Gain; INNOGEN-B Down Over 45% Cumulatively in Two Weeks Since Lock-up Expiry - 20260821
Research
HK Stock Connect Weekly Report: Hang Seng Index Rises 3.55% for the Week; Quarterly Review Results Unveiled, HUA HONG GRACE and ILUVATAR COREX Enter HSI and HSTECH - 20260821
Research
Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
Research
HK Stock Connect Daily Report: MINIMAX-W Up Nearly 12%, Z.AI Up Over 10%, Southbound Net Sell of HKD 7.6 Billion - 20260821
Finance
Ingenic Semiconductor (03223.HK): H-Shares Offer Price Set at HK$100 Per Share
Finance
MOBVOI (02438.HK): Expects H1 Loss of RMB 45-58 Million
Finance
FAR INTL (02516.HK): Expects H1 Revenue Up 61%-110% and Turnaround or Narrower Loss
Finance
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
Finance
LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Finance
SC HOLDINGS (00413.HK): Expects H1 Net Loss of HKD 400-500 Million
Scan QR Code
Download App
